0
Skip to Content
CANCER PROFILING AUSTRALIA
Home
Services
exacta
celldx
cancertrack
chemo-scale
About
News & Events
Publications
Contact
CANCER PROFILING AUSTRALIA
Home
Services
exacta
celldx
cancertrack
chemo-scale
About
News & Events
Publications
Contact
Home
Folder: Services
Back
Services
exacta
celldx
cancertrack
chemo-scale
About
News & Events
Publications
Contact
Golden milk
Recipe Dr. Joachim Fluhrer 05/05/2020 Recipe Dr. Joachim Fluhrer 05/05/2020

Golden milk

Read More
Ginger soda
Recipe Dr. Joachim Fluhrer 28/04/2020 Recipe Dr. Joachim Fluhrer 28/04/2020

Ginger soda

It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more.

Read More

ASCO 2026 — Datar Cancer Genetics Research

Datar Cancer Genetics presented 14 abstracts at the ASCO Annual Meeting 2026, covering molecular diagnostics, multi-omics, immunotherapy biomarkers, pharmacogenomics, and comprehensive genomic profiling across solid tumours. Cancer Profiling Australia makes this research available to oncologists across Australia and New Zealand.

All abstracts published with permission. ©2026 American Society of Clinical Oncology, all rights reserved.

  • A hybrid tumor-informed and tumor-agnostic ctDNA MRD platform detected clinically occult molecular disease in 27.1% of imaging-negative early breast cancer patients. MRD preceded imaging-confirmed recurrence by a median of 9.75 months. VIEW ABSTRACT

  • 40.4% of ESR1 wild-type HR⁺/HER2⁻ breast cancers harboured clinically relevant resistance alterations across PI3K/AKT, FGFR, ERBB2, MAPK, and cell-cycle pathways. Comprehensive genomic profiling beyond ESR1 is essential for guiding therapy selection. READ ABSTRACT

  • A real-world multi-omic analysis of 823 CRC samples characterised prostaglandin pathway activation in PIK3CA-mutant tumours, providing mechanistic rationale for aspirin benefit in this biologically distinct CRC subset. READ ABSTRACT

  • Despite converging on MAPK signalling, KRAS and BRAF mutations in CRC drive distinct and non-overlapping transcriptomic programs. KRAS-mutant tumours show immune-excluded microenvironments; BRAF-mutant tumours exhibit tumour-intrinsic RNA regulatory rewiring.
    READ ABSTRACT

  • 30.6% of TMB-high solid tumours harboured intrinsic immune resistance alterations, structured around a PTEN–WNT–B2M genomic axis. TMB reflects immune pressure — not immune competence. READ ABSTRACT

  • 40.2% of BRAF-mutant solid tumours harbour non-V600E alterations outside current targeted therapy paradigms. Pancreatic, gastric, breast, and ovarian cancers are enriched for non-V600 BRAF biology — a disproportionate unmet clinical need. READ ABSTRACT

  • Large genomic rearrangements constitute a non-trivial component of germline BRCA pathogenic variation, showing preferential BRCA1 involvement and enrichment in ovarian cancer. 12.1% of individuals harboured germline alterations with direct therapeutic relevance including PARP inhibitor eligibility. READ ABSTRACT

  • ETA-guided personalised therapy in the RESILIENT trial achieved an ORR of 42.9% and CBR of 90.5%, exceeding historical precision medicine benchmarks, with cost per month of PFS approximately half that of sequential standard-of-care. READ ABSTRACT

  • TMB-high colorectal cancers exhibit a distinct molecular phenotype defined by KRAS/PIK3CA driver enrichment, RBP4/MDK upregulation, and depletion of stromal markers — suggesting novel therapeutic vulnerabilities beyond immune checkpoint inhibition. READ ABSTRACT

  • 43.8% of glioma samples harboured at least one actionable alteration with an FDA-approved therapy. IDH-wildtype gliomas were enriched for cross-indication biomarkers, supporting comprehensive molecular profiling to guide expanded indication therapies. READ ABSTRACT

  • Nearly 5% of cancer patients were classified as intermediate or poor DPYD metabolisers in a cohort of 4,380 individuals. Several clinically actionable diplotypes would not have been detected by conventional PCR-based assays — with direct implications for safer fluoropyrimidine dosing. READ ABSTRACT

  • Multi-algorithm transcriptomic profiling identified immune-enriched low-grade and immune-excluded high-grade CNS tumours, characterised by Treg-associated immunosuppression and vascular enrichment — supporting TME-guided stratification and novel combination therapy strategies. READ ABSTRACT

  • Paired DNA and transcriptome profiling of 192 CRC patients demonstrated biologically coherent driver–pathway concordance: APC mutations drove WNT/β-catenin activation; SMAD4 mutations lowered TGF-β signalling. READ ABSTRACT

  • At least one ADC-relevant target was identified in 60.5% of 1,903 solid tumour samples using transcriptome-wide RNA profiling. CLDN18.2 IHC concordance demonstrated 92.6% overall accuracy, supporting RNA-based ADC biomarker assessment as a clinical complement to DNA profiling. READ ABSTRACT

Hours

Monday – Friday
9.00am – 5.00pm (AEST)

Follow

CERTIFICATIONS/ACCREDITATIONS OF DATAR CANCER GENETICS INDIA

CANCER PROFILING AUSTRALIA

526/368 Sussex St, SYDNEY

NSW 2000 Australia

PH +61 07 5600 1499
Email: info@cancerprofiling.com.au